| Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... Journal of Clinical Oncology 38 (3), 193-202, 2020 | 1473 | 2020 |
| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma … V Vilgrain, H Pereira, E Assenat, B Guiu, AD Ilonca, GP Pageaux, A Sibert, ... The Lancet Oncology 18 (12), 1624-1636, 2017 | 783 | 2017 |
| Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer DY Oh, A Ruth He, S Qin, LT Chen, T Okusaka, A Vogel, JW Kim, ... NEJM evidence 1 (8), EVIDoa2200015, 2022 | 440 | 2022 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 259 | 2023 |
| Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma M Bouattour, E Raymond, S Qin, AL Cheng, U Stammberger, G Locatelli, ... Hepatology 67 (3), 1132-1149, 2018 | 229 | 2018 |
| Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, VV Breder, ... Journal of Clinical Oncology 37 (15_suppl), 4004-4004, 2019 | 211 | 2019 |
| Macrotrabecular‐massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance M Ziol, N Poté, G Amaddeo, A Laurent, JC Nault, F Oberti, C Costentin, ... Hepatology 68 (1), 103-112, 2018 | 196 | 2018 |
| A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract … DY Oh, AR He, S Qin, LT Chen, T Okusaka, A Vogel, JW Kim, ... Journal of Clinical Oncology 40 (4_suppl), 378-378, 2022 | 194 | 2022 |
| KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... J Clin Oncol 38 (3), 193-202, 2020 | 190 | 2020 |
| Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in … M Ronot, M Bouattour, J Wassermann, O Bruno, C Dreyer, B Larroque, ... The oncologist 19 (4), 394-402, 2014 | 172 | 2014 |
| Systemic treatment for advanced hepatocellular carcinoma M Bouattour, N Mehta, AR He, EI Cohen, JC Nault Liver cancer 8 (5), 341-358, 2019 | 99 | 2019 |
| Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib S Faivre, M Zappa, V Vilgrain, E Boucher, JY Douillard, HY Lim, JS Kim, ... Clinical Cancer Research 17 (13), 4504-4512, 2011 | 93 | 2011 |
| Immune-related hepatitis with immunotherapy: are corticosteroids always needed? ML Gauci, B Baroudjian, C Zeboulon, C Pages, N Poté, O Roux, ... Journal of Hepatology 69 (2), 548-550, 2018 | 84 | 2018 |
| Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib V Ozenne, V Paradis, S Pernot, C Castelnau, MP Vullierme, M Bouattour, ... European journal of gastroenterology & hepatology 22 (9), 1106-1110, 2010 | 84 | 2010 |
| ESM1 as a marker of macrotrabecular-massive hepatocellular carcinoma J Calderaro, L Meunier, CT Nguyen, M Boubaya, S Caruso, A Luciani, ... Clinical Cancer Research 25 (19), 5859-5865, 2019 | 76 | 2019 |
| Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area G Amaddeo, R Brustia, M Allaire, M Lequoy, C Hollande, H Regnault, ... JHEP Reports 3 (1), 100199, 2021 | 70 | 2021 |
| Transarterial chemoembolisation enhances programmed death‐1 and programmed death‐ligand 1 expression in hepatocellular carcinoma A Montasser, A Beaufrère, F Cauchy, M Bouattour, O Soubrane, ... Histopathology 79 (1), 36-46, 2021 | 64 | 2021 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 58 | 2023 |
| 56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced … DY Oh, AR He, S Qin, LT Chen, T Okusaka, A Vogel, JW Kim, ... Annals of Oncology 33, S565-S566, 2022 | 56 | 2022 |
| Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma H Marijon, S Dokmak, V Paradis, M Zappa, I Bieche, M Bouattour, ... Journal of hepatology 54 (5), 1073-1078, 2011 | 54 | 2011 |
